Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 13,356,950
  • Shares Outstanding, K 385,816
  • Annual Sales, $ 3,236 M
  • Annual Income, $ -3,561 M
  • EBIT $ -3,945 M
  • EBITDA $ -3,851 M
  • 60-Month Beta 1.86
  • Price/Sales 4.09
  • Price/Cash Flow N/A
  • Price/Book 1.21

Options Overview Details

View History
  • Implied Volatility 75.29% ( -4.47%)
  • Historical Volatility 76.99%
  • IV Percentile 71%
  • IV Rank 65.77%
  • IV High 92.67% on 12/18/24
  • IV Low 41.88% on 05/17/24
  • Put/Call Vol Ratio 0.16
  • Today's Volume 145,352
  • Volume Avg (30-Day) 102,735
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 888,078
  • Open Int (30-Day) 857,757

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -2.90
  • Number of Estimates 10
  • High Estimate -1.26
  • Low Estimate -3.64
  • Prior Year -3.07
  • Growth Rate Est. (year over year) +5.54%

Price Performance

See More
Period Period Low Period High Performance
1-Month
29.35 +17.96%
on 03/04/25
38.12 -9.18%
on 03/13/25
+1.63 (+4.94%)
since 02/14/25
3-Month
29.25 +18.36%
on 02/14/25
48.92 -29.23%
on 01/07/25
-7.21 (-17.24%)
since 12/13/24
52-Week
29.25 +18.36%
on 02/14/25
170.47 -79.69%
on 05/24/24
-68.84 (-66.54%)
since 03/14/24

Most Recent Stories

More News
Down 93%, Is It Finally Time to Buy Moderna?

As we near the five-year anniversary of the COVID-19 pandemic, it's a good time to revisit the drugmaker stock that was top of mind back then. A few years ago, Moderna (NASDAQ: MRNA) stock soared on the...

MRNA : 34.62 (+0.93%)
PFE : 25.72 (+0.47%)
3 Reasons MRNA is Risky and 1 Stock to Buy Instead

3 Reasons MRNA is Risky and 1 Stock to Buy Instead

TDG : 1,346.50 (+1.22%)
MRNA : 34.62 (+0.93%)
Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares

Moderna stock has fallen to levels not seen in 5 years, but the CEO just spent $5 million buying stock in the open market underscoring his optimism for gains.

MRK : 94.57 (-0.15%)
MRNA : 34.62 (+0.93%)
Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks

MYGN : 10.07 (+3.81%)
BMRN : 69.44 (-1.64%)
GILD : 111.44 (-1.69%)
ABBV : 211.77 (+0.10%)
MRNA : 34.62 (+0.93%)
Where Will Vertex Pharmaceuticals Be in 10 Years?

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX) . The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since gained...

VRTX : 504.77 (+0.37%)
MRNA : 34.62 (+0.93%)
BioNTech Surpasses Q4 Revenue Estimates

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

MRNA : 34.62 (+0.93%)
PFE : 25.72 (+0.47%)
BNTX : 99.47 (+2.06%)
Here's Why Moderna Stock Soared 16% on Wednesday

Shares of Moderna MRNA rose nearly 16% yesterday after a couple of SEC filings showed that two board members bought shares on the open market. It also secured a legal victory in a patent dispute against...

MRNA : 34.62 (+0.93%)
PFE : 25.72 (+0.47%)
BNTX : 99.47 (+2.06%)
Stocks Plunge Before the Open on Higher Bond Yields and Weak Tech Earnings

March S&P 500 E-Mini futures (ESH25) are down -0.92%, and March Nasdaq 100 E-Mini futures (NQH25) are down -1.14% this morning as higher Treasury yields, trade war worries, and disappointing tech earnings...

NVDA : 121.67 (+5.27%)
CRWD : 353.73 (+6.38%)
AVGO : 195.54 (+2.18%)
GM : 48.34 (+2.61%)
F : 9.73 (+2.10%)
KR : 65.10 (-1.51%)
AF.FP : 9.890 (-0.48%)
BJ : 109.07 (+0.96%)
MU : 100.79 (+6.23%)
MDB : 185.37 (+0.15%)
DHL.D.DX : 42.600 (+2.21%)
ESH25 : 5,640.00s (+2.04%)
Why Moderna Stock Zoomed Nearly 16% Higher on Wednesday

A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price surge on Hump Day. The win by the company, best known as the producer of the Spikevax...

$SPX : 5,638.94 (+2.13%)
MRNA : 34.62 (+0.93%)
PFE : 25.72 (+0.47%)
Stocks Stabilize and Close Higher as Chip Stocks Rally

The S&P 500 Index ($SPX ) (SPY ) Wednesday closed up +1.12%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.14%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.36%. March E-mini S&P...

MPC : 141.15 (+3.01%)
CARR : 66.53 (+3.55%)
APP : 292.89 (+7.68%)
F : 9.73 (+2.10%)
BF.A : 34.47 (+0.06%)
$IUXX : 19,704.64 (+2.49%)
ASML : 714.00 (+2.79%)
ZNM25 : 110-205s (-0.27%)
OXY : 46.53 (+2.38%)
PDD : 122.54 (+3.18%)
ESH25 : 5,640.00s (+2.04%)
FANG : 150.20 (+3.02%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 37.21
2nd Resistance Point 36.53
1st Resistance Point 35.57
Last Price 34.62
1st Support Level 33.93
2nd Support Level 33.25
3rd Support Level 32.29

See More

52-Week High 170.47
Fibonacci 61.8% 116.52
Fibonacci 50% 99.86
Fibonacci 38.2% 83.20
Last Price 34.62
52-Week Low 29.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar